We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

NEW YORK, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Merck & Co. Inc. closed 41.19% below its 52-week high of $134.63, which the company reached on June 25th.

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Merck is juggling shareholder rebellion and market turbulence ahead of its annual meeting, with the company giving a firm thumbs-down to several investor proposals. This shareholder pushback adds a ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Charly AI. In this article, we will summarize the ...

Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...

DelveInsight's Merkel Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, Merkel cell carcinoma emerging drugs, market share of individual ...

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...

Nvidia GTC 2025 Live: Blackwell in Full Production and Demand 'Is Incredible,' Says Huang; Next-Gen Rubin System To Launch in 2026 ...

This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies ...

The company attributed the loss to rises in medical expenses, especially in Medicare and Medicaid, that were not offset by ...